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in terms of health outcome as well as in terms of cost for
high-risk patients from the perspective of the individual
patient as well as of the health care payer. However, this
effect is sensitive to time of treatment start, diagnostic cer-
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OBJECTIVE: Pneumococcical vaccine is an affective pre-
ventive intervention to prevent pneucoccical pneumonia.
In this study, cost-effectiveness of pneumococcical vacci-
nation (23 serotipes) strategies in individuals aged 5 or
more years was assessed. METHODS: Cost-effectiveness
was measured in terms of cost per life year gained (LYG),
comparing net programme costs and effectiveness. The
net programme cost was calculated from vaccinating
costs, assuming 70% compliance, less reduced health
costs from pneumococcical pneumonia achieved with the
programme. Vaccination costs were calculated taking into
account a cost of €11,51 per vaccine. Costs and beneﬁts
were estimated for 1996 using a 5% discount rate.
RESULTS: A cost-effectiveness ratio of €9.023,27 per
LYG was obtained for the universal vaccination of the
population. The cost-effectiveness ratio was €113.177,12
per LYG in individual aged 5–24 years, €19.482,51 per
LYG in those aged 25–44 years, €7.122,80 per LYG in
those aged 45–64y < 0 in those aged >64 years. In the
age group of >64 years, disease costs reduced were higher
than vaccination costs, with a savings/costs ratio of 1,58.
Results of cost-effectiveness analysis were sensitive to the
vaccine price, vaccine efﬁcacy and the percentage of pneu-
monias caused by S. pneumoniae, being less sensitive to
health costs from pneumococcical pneumonia, hospital-
ization rate in patients with a community acquired pneu-
monia and vaccination compliance. CONCLUSION:
Results obtained in this study shows that pneumococci-
cal vaccination should be a priority preventive interven-
tion in individuals aged >64 and 45–64 years.
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OBJECTIVES: For many diseases, a small number of
complicated cases accounts for the main part of the costs.
Our aim was to investigate the relevance of complications
for the overall costs of varicella in Germany in order 
to assess whether vaccination strategies targeting at risk
groups, e.g. adolescents, have the potential to sub-
stantially reduce the economic burden of varicella.
METHOD: A decision-analytic model, the Economic
Varicella VaccInation Tool for Analysis (EVITA), was
used to analyze epidemiological and economic effects of
varicella over a period of 30 years as varicella incidence
ﬂuctuates over time and, thus, a typical cost of illness
study performed in one year might provide biased esti-
mates of overall costs. Input data on the epidemiology 
of varicella and its complications as well as the respec-
tive resource use were derived from two large surveys.
RESULTS: Complications occur in 5.7% of the annual
average of 739,000 cases. Overall annual costs are €187.5
million from the societal and €78 million from the payers’
perspectives. From the payers’ (societal) perspective
32.0% (24.7%) of the overall costs can be attributed 
to complications. Complications account for 53.8%
(53.3%) of the direct medical costs and 15.5% (18.3%)
of the indirect costs. When complications occur, inpatient
care (67.7%) from the payers’ and work loss (60.9%)
from the societal perspectives are the main cost drivers 
of complications. Pneumonia accounts for the majority 
of the costs of complications. For uncomplicated 
courses of varicella, the indirect costs of work loss are 
the major cost factor. CONCLUSIONS: Complications
account for a disproportionate part of overall disease
costs. However, uncomplicated courses account for the
vast majority of costs. Vaccination strategies targeting
only on risk groups with high risks of complications
might therefore fail to substantially reduce the consider-
able economic burden of varicella.
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OBJECTIVE: In Japan, measles vaccine coverage is lower
than 80% nationwide. As a result, the number of measles
case is estimated about 100,000–200,000 a year. In this
study, we performed cost-beneﬁt analysis between the
cost of vaccination and the cost of treatment of measles.
Although cost effectiveness analysis including cost-beneﬁt
analysis of vaccination is extensively performed (e.g.
inﬂuenza), it is not carried out concerning measles at all.
This research is unique in this point of view. METHODS:
We conducted chart investigation of 291 measles patients
(171 outpatient cases and 120 hospitalization cases) in
one hospital from July 1997 to September 2001. Among
them, medical expenses were calculated about 121
samples of outpatients and 112 inpatients which are 
considered to be appropriate for the contents of medical
treatment. At the same time, we estimated opportunity
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cost from the employment situation of the parents of 
the child patients from the chart and the interview. Loss
proﬁts were taken into consideration about death cases
or the critical sequelae. RESULTS: Medical expenditure
in outpatient cases was about 120,000 yen on average,
while it was 300,000 yen for hospitalization cases. The
opportunity cost was far exceeded medical expenses.
Beneﬁt Cost ratio (BCR) was 2.5, when the base case was
set up and was presumed. In the result of sensitive analy-
sis of BCR, it ranged from 2.3 at a minimum to about 5
at the maximum. Discussion in the preceding research on
the BCR analysis of vaccination, it is well-known that
BCR is 1.4 for hepatitis B vaccine for infants, 1.93 for
inﬂuenza vaccine for pre-school children, and 1.81 for
inﬂuenza vaccine for healthy adults. When compared
with this research, the result of this research shows the
validity of a measles vaccine strongly. CONCLUSION:
We conclude that measles vaccination is excellent method
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OBJECTIVES: The aim of the study was to compare the
highly active antiretroviral therapy either with ritonavir
(RTV)/saquinavir (SQV), lopinavir/ritonavir (LPV/RTV),
indinavir (IDV), nelﬁnavir (NFV) or efavirenz (EFV) in
combination with two nucleoside reverse transcriptase
inhibitors therapy. METHODS: The cost-effectiveness
analysis was conducted. Clinical data were derived from
published clinical trials and large observational cohorts.
The analysis was based on the drug costs solely, obtained
from National AIDS Centre in Poland. Three scenarios
were investigated in the research. The ﬁrst one extended
over a time of 48 weeks of the treatment with a studied
NNRTI or PI. A measure of effectiveness was deﬁned as
a virological suppression of serum HIV-RNA <400
copies/mL at the end of the treatment. In the second 
scenario the initial therapy for HIV infection could be
switched twice in patients who failed their PI- or NNRTI-
based treatment regimen. The time horizon of the analy-
sis was set to 144 weeks, i.e. 3 cycles—48 weeks each. A
measure of effectiveness was deﬁned as virological sup-
pression at any point of time during the whole time
horizon. In the third scenario the time horizon lasted for
10 cycles (480 weeks) of HIV-infection treatment, with
two changes of treatment regimens in case of failure. In
this scenario the measure of effectiveness was deﬁned 
as a number of cycles with a serum HIV-RNA <400
copies/ml. RESULTS: LPV/RTV proved to be the most
cost-effective combination in the ﬁrst two scenarios
having the cost-effectiveness ratio (C/E ratio) of 22987
PLN (Polish zlotys) and 23594 PLN, respectively. In the
third scenario EFV was the most cost-effective therapy
with a C/E ratio of 15254 PLN. The sensitivity analysis
turned out in all scenarios the combination LPV/RTV 
had the smallest standard error of C/E ratio proving to
be more attractive. The sensitivity analysis proved the
robustness of the obtained results against the assumptions
taken. CONCLUSIONS: Depending on the scenario pre-
sumed either the therapy containing LPV/RTV or EFV is
the most cost-effective alternative of the treatment of
HIV-infection in Poland.
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OBJECTIVES: To estimate the hospitalisation costs, both
on average and for selected subgroups, for severe infec-
tion with the respiratory syncytial virus (RSV) in young
children. METHODS: We collected data of children hos-
pitalised for severe RSV infection during four seasons
1996/97, 1997/98, 1998/99, and 1999/2000 in 29 hospi-
tals in the Southwest of The Netherlands (n = 3,487). Five
patient characteristics (sex, gestational age, presence of
bronchopulmonary disease (BPD), birth weight and age)
were collected for all patients together with the number
of hospital days. In addition, detailed information of 20
resources related to daily hospital care was collected 
for children hospitalised in the last season (1999/2000).
Volumes of care were obtained from hospital registries
and questionnaires among nurses and physicians. Prices
were based on hospital accounts and national salary
guidelines. For the last season (n = 946), the individual
total hospitalisation costs were directly calculated. We
estimated the costs for the children hospitalised in the ﬁrst
three seasons (1996/97, 1997/98, and 1998/99) based on
the correlation of costs with the number of hospital days
and the 5 patient characteristics using a linear regres-
sion model. RESULTS: The number of hospital days
accounted for >80% of the variety in total hospitalisation
costs in the season 1999/2000. The average total costs of
the season 1999/2000 were €3,135 per child. The costs
for children with low gestational age were considerably
higher (€5,325 for a child with gestational age ‹28
weeks). Also, hospitalisation of a child with BPD was
more expensive (€5,870). CONCLUSIONS: The hospital
related costs of severe RSV infections in young children
were primarily determined by the number of hospital
days. Therefore, we could estimate the hospitalisation
costs for four RSV seasons, although detailed informa-
